Global Information
회사소개 | 문의 | 비교리스트

평활근육종 : 파이프라인 리뷰

Leiomyosarcoma (Oncology) - Drugs In Development, 2021

리서치사 Global Markets Direct
발행일 2021년 07월 상품 코드 247798
페이지 정보 영문 827 Pages
가격
US $ 2,000 ₩ 2,431,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,862,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,293,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


평활근육종 : 파이프라인 리뷰 Leiomyosarcoma (Oncology) - Drugs In Development, 2021
발행일 : 2021년 07월 페이지 정보 : 영문 827 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

평활근육종은 자궁이나 위장 등 연부조직의 전형적인 평활근세포에서 발생하는 악성 연부조직 육종입니다. 증상은 만지면 느껴지는 덩어리나 혹이며, 신경이나 근육을 압박하면 통증이 있습니다. 또, 종양이 복부와 위장에 있으면 위장의 장애물이 되어 소화관 출혈을 일으키기도 합니다. 발병 원인으로 연령, 화학물질 노출, 방사선 노출 등을 들 수 있습니다. 치료법에는 화학요법, 방사선치료, 외과적 수술이 있습니다.

평활근육종(Leiomyosarcoma) 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 최신 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보 등을 전해드립니다.

서론

  • 조사 범위
  • 평활근육종 개요

치료제 개발

  • 파이프라인 제품;개요
  • 파이프라인 제품;비교 분석

기업에서 개발중인 치료제

대학/기관에서 연구중인 치료제

평활근육종 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Advenchen Laboratories, LLC
  • BeiGene, Ltd.
  • Cell Medica Limited
  • Karyopharm Therapeutics, Inc.
  • Merck & Co., Inc.
  • Mirati Therapeutics Inc.
  • Novartis AG
  • Vicore Pharma AB

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • AL-3818
  • BGB-290
  • C-21
  • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases
  • CMD-003
  • everolimus
  • mocetinostat
  • NOV-110501
  • pazopanib hydr
  • pembrolizumab
  • selinexor

평활근육종 : 최근의 파이프라인 동향

평활근육종 : 휴지 상태인 프로젝트

개발이 중지된 제품

부록

도표

LSH 16.04.22

List of Tables

List of Tables

  • Number of Products under Development for Leiomyosarcoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Leiomyosarcoma - Pipeline by Actuate Therapeutics Inc, 2021
  • Leiomyosarcoma - Pipeline by Advenchen Laboratories LLC, 2021
  • Leiomyosarcoma - Pipeline by Alphamab Oncology, 2021
  • Leiomyosarcoma - Pipeline by ALX Oncology Holdings Inc, 2021
  • Leiomyosarcoma - Pipeline by Apexigen Inc, 2021
  • Leiomyosarcoma - Pipeline by Apollomics Inc, 2021
  • Leiomyosarcoma - Pipeline by AstraZeneca Plc, 2021
  • Leiomyosarcoma - Pipeline by Atara Biotherapeutics Inc, 2021
  • Leiomyosarcoma - Pipeline by BeiGene Ltd, 2021
  • Leiomyosarcoma - Pipeline by BioAtla Inc, 2021
  • Leiomyosarcoma - Pipeline by BioMed Valley Discoveries Inc, 2021
  • Leiomyosarcoma - Pipeline by Cebiotex SL, 2021
  • Leiomyosarcoma - Pipeline by Clovis Oncology Inc, 2021
  • Leiomyosarcoma - Pipeline by CStone Pharmaceuticals Co Ltd, 2021
  • Leiomyosarcoma - Pipeline by Eli Lilly and Co, 2021
  • Leiomyosarcoma - Pipeline by ENB Therapeutics LLC, 2021
  • Leiomyosarcoma - Pipeline by Exelixis Inc, 2021
  • Leiomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, 2021
  • Leiomyosarcoma - Pipeline by Immodulon Therapeutics Ltd, 2021
  • Leiomyosarcoma - Pipeline by Incyte Corp, 2021
  • Leiomyosarcoma - Pipeline by Karyopharm Therapeutics Inc, 2021
  • Leiomyosarcoma - Pipeline by Kuur Therapeutics Ltd, 2021
  • Leiomyosarcoma - Pipeline by Merck & Co Inc, 2021
  • Leiomyosarcoma - Pipeline by Merck KGaA, 2021
  • Leiomyosarcoma - Pipeline by Millennium Pharmaceuticals Inc, 2021
  • Leiomyosarcoma - Dormant Projects, 2021
  • Leiomyosarcoma - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Leiomyosarcoma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leiomyosarcoma - Drugs In Development, 2021, provides an overview of the Leiomyosarcoma (Oncology) pipeline landscape.

Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal or soft tissue origin. Symptoms include a noticeable lump or swelling, pain, if it presses on nerves or muscles and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure and radiation exposure. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leiomyosarcoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Leiomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leiomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Leiomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I and IND/CTA Filed stages are 1, 21, 16 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Leiomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leiomyosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Leiomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leiomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leiomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leiomyosarcoma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leiomyosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leiomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Leiomyosarcoma - Overview
  • Leiomyosarcoma - Therapeutics Development
  • Leiomyosarcoma - Therapeutics Assessment
  • Leiomyosarcoma - Companies Involved in Therapeutics Development
  • Leiomyosarcoma - Drug Profiles
  • Leiomyosarcoma - Dormant Projects
  • Leiomyosarcoma - Discontinued Products
  • Leiomyosarcoma - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q